We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Simple Blood Test Monitors Compliance of Diabetic Patients

By HospiMedica International staff writers
Posted on 17 Jun 2010
A simple blood test that checks whether diabetes is under control is now available. More...
The point-of-care test will enable physician to get results rapidly without the patient fasting.

The percentage of glycosalated hemoglobin (HbA1c) in the blood can now be measured with a hand held device that will give results in about three minutes. This will help physicians track a diabetic patient's glycemic control over the prior six to twelve week period.

The test, called the Avie A1c test, is an addition to HemoCue systems offered by Quest Diagnostics, (Quest Diagnostics Inc., Madison, NJ, USA) who have reached an agreement with MEC Dynamics (MEC Dynamics Corp, Santa Clara , CA, USA), to distribute it in the U.S. A. and Europe. The test is a more accurate way of testing diabetic patients' compliance with the treatment regime as HbA1c changes very slowly over a 10-12 week period, while glucose levels can vary daily.

HemoCue, with the addition of the Avie A1c test, will be able to offer a more complete suite of point-of-care (POC) tests for efficient diabetes management. Physicians can test for and diagnose the disease using the HemoCue Glucose 201 systems. They can monitor for diabetes-related complications with the HemoCue Albumin 201 test for microalbuminuria, a kidney and cardiovascular disease risk marker.

Jon R. Cohen, M.D., senior V.P. and chief medical officer at Quest Diagnostics said, "Having quality values at the point of care creates an opportunity for a physician to ask questions, discuss patient lifestyle, review medication history, and adjust treatment course as appropriate."

Diabetes is characterized by glucose intolerance and hyperglycemia. The latter represents a high level of glucose in the blood, which, if not properly monitored and managed, can lead to serious complications such as renal and cardiovascular disease. Diabetes was the seventh leading cause of death listed on U.S. death certificates in 2006, and it is estimated that about 8% of the U.S. and 7.8% European populations suffer from the disease.

Related Links:

Quest Diagnostics Inc.
MEC Dynamics Corp



Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
ow Frequency Pulse Massager
ET10 L
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image: The fiber in the brain implant is less than half a millimeter thick (Photo courtesy of Peter Aagaard Brixen)

Brain Implant Records Neural Signals and Delivers Precise Medication

Neurological diseases such as epilepsy involve complex interactions across multiple layers of the brain, yet current implants can typically stimulate or record activity from only a single point.... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.